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EDITORIAL 
Progressive Supranuclear Palsy: 
Postmortem Chemical Analysis 
Over the past two decades, the postmortem analysis of 
brain neurotransmitters, neurohormones, metabolites, 
and neurotransmitter-related enzymes has yielded im- 
portant information about the pathophysiological basis 
of human neurodegenerative disorders such as Parkin- 
son’s, Huntington’s, and Alzheimer’s diseases. Such 
studies have led to the investigation of new and more 
specific therapies for these degenerative diseases. Fol- 
lowing in this issue, two independent groups of in- 
vestigators report their findings on the postmortem 
neurochemistry of progressive supranuclear palsy 
(PSP). These studies by Kish‘s and Ruberg’s groups 
shed light on the pathophysiological characteristics of 
PSP as well as on Parkinson’s and Alzheimer’s dis- 
eases. 
PSP was first described clinically in 1904 [l] but was 
only defined as a specific clinicopathological entity in 
1964 by Steele, Richardson, and Olszewski [ 2 ,  3 J. PSP 
is uncommon and accounts for about 4% of patients 
who manifest parkinsonian symptoms 111. The onset 
of the disease is usually in the sixth decade, and it is 
somewhat more common in men than in women. The 
average duration of the disease is less than 10 years. 
This is similar to untreated Parkinson’s disease, which 
has an average duration of about 7 to 10 years. The 
classic features of PSP are supranuclear ophthal- 
moparesis, bradykinesia, axial rigidity, postural insta- 
bility, and pseudobulbar affect. Vertical-gaze paresis, 
especially down-gaze paresis, is the most common 
oculomotor sign. Bradykinesia and rigidity often de- 
velop early and can lead to an initial diagnosis of Par- 
kinson’s disease. In contrast to Parkinson’s disease, 
however, tremor is unusual. Depression and irritability 
are common features, and dementia is frequently seen 
as the disease progresses. 
The neurochemical abnormalities reported by 
Ruberg’s and Kish‘s groups are in close agreement 
with each other. Their findings should enhance our 
understanding of basal gangha function in general and 
of PSP in particular. Ruberg’s group studied 9 cases of 
PSP, and Kish‘s group studied 5 cases. The most strik- 
ing finding of both groups was a marked reduction in 
the concentrations of dopamine (80 to 90%) and 
homovanillic acid (HVA) (45 to 50%) in the caudate 
and putamen. Furthermore, the more marked reduc- 
tion in dopamine concentrations as compared to HVA 
levels suggests an increased turnover of dopamine in 
the remaining dopamine terminals in the caudate and 
putamen. These observed reductions in dopamine and 
HVA concentrations are somewhat less marked than, 
but otherwise similar to, those seen in Parkinson’s dis- 
ease and provide a probable explanation for the axial 
rigidity and bradykinesia seen clinically in PSP. 
In contrast to Parkinson’s disease, however, both 
groups found normal dopamine and HVA levels in the 
nucleus accumbens. Kish and co-workers also mea- 
sured norepinephrine and serotonin levels, which were 
generally normal. In Parkinson’s disease, the loss of 
dopamine in the nucleus accumbens and limbic cortex 
has been hypothesized as a cause of depressive symp- 
toms. This hypothesis is now in question because de- 
pression and dementia are common in PSP while 
dopaminergic function in mesolimbic and mesocortical 
pathways is normal. One would have to postulate 
either that there is a difference in the type or cause of 
depression seen in PSP versus Parkinson’s disease or 
that the involvement of noniimbic areas such as the 
caudate nucleus must be considered as an alternate 
explanation for the depression seen in these two dis- 
eases. In this regard, it is of interest that in Hunting- 
ton’s disease, depression is also very common, but, 
again, the nucleus accumbens is relatively spared. 
Both groups of investigators measured choline 
acetyltransferase (CAT) activity in several brain re- 
gions. Ruberg and co-workers found a mild (approxi- 
mately 20%) decrease of CAT activity in the cerebral 
cortex; moderate decreases (40 to 60%) in the cau- 
date, putamen, and nucleus accumbens; and an even 
larger decrease (70%) in the substantia innominata 
(the presumed source of a large number of cholinergic 
cortical afferents). In contrast, Kish and colleagues 
found no significant changes in CAT activity in the 
cerebral cortex or basal gangha, even in 2 of the 5 PSP 
patients with documented severe dementia. This dis- 
crepancy must be resolved in further studies. Reported 
pathologic findings in the substantia innominata in 
PSP, although not as marked as those in Alzheimer’s 
disease, are most consistent with the existence of at 
least some cholinergic deficits [4]. Neither group, 
however, found changes approaching the decreases in 
cerebral cortical CAT that have been found in Alz- 
heimer’s disease (85 to 95%). Thus, it is unlikely that 
the dementia in PSP is caused primarily by cortical 
cholinergic deficits. Ruberg and colleagues suggest that 
the decreases in CAT activity in the substantia in- 
nominata are likely caused by a loss of cholinergic af- 
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ferents to the substantia innominata from the brain- 
stem. Such an explanation is consistent with the mild 
decrease in postsynaptic cholinergic receptors in the 
substantia innominata (approximately 26%) and the 
equally mild changes in cortical CAT activity (approxi- 
mately 2 1%). 
Ruberg and co-workers measured dopamine recep- 
tors using the potent D-2 antagonist [3H)spiperone. 
[3H}spiperone binding was decreased 40 to 50% in 
the caudate, putamen, and nucleus accumbens. 
Dopamine receptors were also decreased 34% in the 
frontal cortex and 67% in the substantia innominata. 
These decreases could be related either to drug ther- 
apy or to cell loss in the regions measured. Five of 
their PSP patients were treated until death with 
dopamine agonists, and all patients were treated with 
them at some point during their illness. Dopamine 
agonists may have caused a down-regulation in 
dopamine receptors throughout the brain. Alterna- 
tively, cell loss would lead to loss of receptors as most 
dopamine D-2 receptors are located on the intrinsic 
neurons that receive dopamine input. Cell loss would 
also provide an explanation for the loss of CAT activ- 
ity in the caudate, putamen, and nucleus accumbens, 
structures that normally have large numbers of cholin- 
ergic interneurons. Ruberg and associates found a 
significant correlation between the decreases in CAT 
activity in various areas and the decreases in dopamine 
receptors. The loss of cholinergic interneurons in the 
basal ganglia may provide a possible explanation for 
the relative lack of effectiveness of dopamine agonists 
and cholinergic antagonists in PSP as compared with 
Parkinson’s disease, as dopamine is thought to exert its 
pharmacological effects to a large extent through inhi- 
bition of cholinergic interneurons. The loss of cholin- 
ergic interneurons may also explain the lack of tremor 
in PSP. One of the most prominent effects of anti- 
cholinergic agents in Parkinson’s disease is the relief of 
tremor. In Parkinson’s disease, there is a relative 
underactivity of dopaminergic systems and an overac- 
tivity of cholinergic systems. In PSP, the loss of cholin- 
ergic markers in the basal ganglia tends to restore the 
dopaminergidcholinergic balance. Because the cholin- 
ergic cells are postsynaptic to the dopamine cells, per- 
haps the efficacy of cholinergic agonists should be in- 
vestigated in this disease. 
Kish and co-workers found elevated glutamic acid 
levels in the temporal and occipital cortex, caudate, 
putamen, and medial globus pallidus. Levels of y- 
aminobutyric acid (GABA) were found to be normal 
except in the subthalamic nucleus, where the GABA 
concentration was reduced. Glutamate is thought to be 
the neurotransmitter of cortical neurons projecting 
both to other areas of cerebral cortex and to various 
subcortical areas such as the caudate and putamen. Fur- 
thermore, glutamate has known neurotoxic effects in 
the brain. However, there is little evidence for a direct 
neurotoxic role of glutamate in PSP, as Kish and col- 
leagues found no correlation between the degree of 
elevation of glutamate levels in a given structure and 
the severity of the neurological abnormalities in that 
region. 
In summary, these two groups of investigators have 
presented valuable information that can help us to 
understand the parkinsonian symptoms, the lack of ef- 
fectiveness of drug therapy, and the mild dementia 
observed clinically in PSP. Future studies should focus 
on the brainstem biochemical abnormalities, an under- 
standing of which may help explain the ophthal- 
moparesis and pseudobulbar affect so common in this 
disorder. 
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